JNJJanssen Research & Development, LLCSigning up patients
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 68 (planned)
- Started
- Jul 28, 2026
- Main results expected
- Mar 2, 2028
- Fully finished
- Apr 3, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Pathologic response (MPR)
Measured over: Up to 1 year 8 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07586202 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC